Evidence map›Paper›PMID 40095258›Full record

ArticleInvestigational new drugs2025

Evaluation of the anti-leukemia activity and underlying mechanisms of the novel perinucleolar compartment inhibitor CTI-2 in acute myeloid leukemia.

Anran Li, Mingmin Yu, Yue Zhao, Shuangshuang Wu, Guan Wang, Liping Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anran LiNational Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, School of Life Sciences, The Ministry of Education, Jilin University, 2699 Qianjin Street, Changchun, Jilin Province, China.
Mingmin YuNational Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, School of Life Sciences, The Ministry of Education, Jilin University, 2699 Qianjin Street, Changchun, Jilin Province, China.
Yue ZhaoNational Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, School of Life Sciences, The Ministry of Education, Jilin University, 2699 Qianjin Street, Changchun, Jilin Province, China.
Shuangshuang WuDepartment of Pediatric Hematology, The First Hospital of Jilin University, Changchun, China.
Guan WangNational Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, School of Life Sciences, The Ministry of Education, Jilin University, 2699 Qianjin Street, Changchun, Jilin Province, China. wg10@jlu.edu.cn.
Liping WangNational Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, School of Life Sciences, The Ministry of Education, Jilin University, 2699 Qianjin Street, Changchun, Jilin Province, China. wanglp@jlu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a malignant clonal hematological tumor originating from immature myeloid cells and is the most prevalent type of leukemia in adults. Traditional chemotherapy regimens based on cytarabine and anthracycline agents are associated with a high relapse rate. Therefore, investigation of novel targeted therapies is crucial for improving AML treatment outcomes. In this study, we found that CTI-2, a novel inhibitor of perinucleolar compartment (PNC), has potential anti-AML activity with a favorable safety profile. CTI-2 induced a greater degree of apoptosis in FLT3-ITD mutant AML cells compared to AML cells with wild-type FLT3 mainly through the intrinsic apoptotic pathway. Furthermore, MK2 and Pim-1 were identified as potential targets of CTI-2 through molecular docking analysis. CTI-2 decreased both the overall expression level and the phosphorylation of c-Myc, which are regulated by MK2 and Pim-1, respectively. Notably, CTI-2 exhibited a more substantial inhibitory effect on c-Myc in FLT3-ITD mutant cells, which may contribute to the enhanced efficacy of CTI-2 in this specific subset of AML. In summary, we have conducted a preliminary investigation into the anti-AML activity and underlying mechanisms of CTI-2. These results provide clues for the targeting of PNC in the treatment of AML.

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteApoptosisCell Line, Tumorfms-Like Tyrosine Kinase 3HumansMolecular Docking SimulationProto-Oncogene Proteins c-mycProto-Oncogene Proteins c-pim-1Antineoplastic AgentsFLT3 protein, humanfms-Like Tyrosine Kinase 3PIM1 protein, humanProto-Oncogene Proteins c-mycProto-Oncogene Proteins c-pim-1Acute myeloid leukemiaApoptosisc-MycCTI-2FLT3-ITD

Identifiers

PMID40095258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.